Rapt Therapeutics Inc Expected To Post A Loss Of 64 Cents A Share: Earnings Preview

Rapt Therapeutics

04/08/2025 13:37

RAPT Therapeutics Inc RAPT.OQ RAPT.O is expected to  show no change in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for RAPT Therapeutics Inc is for a loss of 64 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for RAPT Therapeutics Inc is $27.00, about 61.1% above its last closing price of $10.49

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.09
-1.08
-0.64
Beat
40.7
Dec. 31 2025
-2.50
-2.98
-9.12
Missed
-206.5
Sep. 30 2024
-4.57
-4.51
-3.76
Beat
16.7​
Jun. 30 2024
-5.78
-5.76
-5.68
Beat
1.4
​​Mar. 31 2024
-6.41
-6.47
-6.32
Beat
2.3
Dec. 31 2023
-6.86
-6.87
-6.40
Beat
6.8​
Sep. 30 2023
-5.99
-6.03
-6.56
Missed
-8.9
Jun. 30 2023
-6.32
-6.25
-5.28
Beat
15.6

This summary was machine generated August 4 at 12:37 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)